WHITE PAPER
Delivering Transformative Impact in the Southeast Asia Pharmaceutical Industry
May 02, 2023

Over the last few years, pharmaceutical companies in Southeast Asia have seen strong growth in the region. However, the COVID-19 pandemic and emerging key macro-trends are points of impact for the life sciences industry and healthcare systems which has created an environment where Volatility, Uncertainty, Complexity and Ambiguity (VUCA) characterize any business setting today.

Transformation is the need of the hour. This white paper provides an overview of the changing healthcare environment in Southeast Asia, which is driving the need for transformative impact and highlights eight key tenets of transformation for pharmaceutical companies and business leaders to accelerate growth, remain competitive and capture leading positions in the market.

To find out more, contact us.

Authors

  • Puneet Singh, Consultant, Consulting Services, SEA & APAC RHQ, IQVIA
  • Raghav Sharma, Associate Principal, Consulting Services, SEA & APAC RHQ, IQVIA
  • Devaraj Subramaniam, Associate Principal and Malaysia Consulting Lead, Consulting Services, SEA & APAC RHQ, IQVIA
  • Erwin Widjaja, Head of Services, Indonesia, IQVIA
Contact Us